Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -12.32
- Piotroski Score 2.00
- Grade Buy
- Symbol (DARE)
- Company Daré Bioscience, Inc.
- Price $3.23
- Changes Percentage (1.55%)
- Change $0.05
- Day Low $3.18
- Day High $3.26
- Year High $7.56
Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, fertility, and sexual and vaginal health. The company's product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its products in advanced clinical development include Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar and vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan, as well as DARE-PTB1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ADARE-204 and ADARE-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company entered into license agreement with Organon & Co. and Organon International GmbH to commercialize XACIATO. Daré Bioscience, Inc. is headquartered in San Diego, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/06/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.33
- Trailing P/E Ratio -1.58
- Forward P/E Ratio -1.58
- P/E Growth -1.58
- Net Income $-30,161,391
Income Statement
Quarterly
Annual
Latest News of DARE
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Falcons' KhaDarel Hodge turns to faith after scoring game-winning touchdown: 'God is real'
KhaDarel Hodge's unforgettable game-winning touchdown for the Falcons against the Buccaneers left him speechless. Despite a quiet season start, his faith and determination propelled him to a career-de...
By Fox News | 1 day ago -
Gen Z employee blasted for pajama-like work clothes: 'How dare you!'
Chloe, a 29-year-old professional from Sydney, went viral for her work outfit mistaken as pajamas. Despite receiving criticism, her chic matching silk set sparked a debate about office attire trends. ...
By New York Post | 3 days ago -
The week in TV: Ludwig; Celebrity SAS: Who Dares Wins; Apples Never Fall; Surviving October 7; Small Town, Big Riot - review
BBC One's Ludwig, a cozy crime comedy-thriller series, follows David Mitchell as Ludwig, a quirky puzzle-setter turned detective. With a stellar cast and witty moments, the show offers a unique take o...
By The Guardian | 1 week ago
